Claudio Vernieri

List of Publications by Citations

64 papers	1,266 citations	18 h-index	34 g-index
67 ext. papers	1,810 ext. citations	8.6 avg, IF	4.41 L-index

#	Paper	IF	Citations
64	Evidence that Aurora B is implicated in spindle checkpoint signalling independently of error correction. *EMBO Journal*, **2011**, 30, 1508-19	13	149
63	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 2414-2422	12.9	111
62	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. *Cancer Discovery*, **2016**, 6, 1315-1333	24.4	107
61	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open*, **2019**, 4, e000457	6	93
60	Fasting-mimicking diet and hormone therapy induce breast cancer regression. *Nature*, **2020**, 583, 620-624	50.4	79
59	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. *Critical Reviews in Oncology/Hematology*, **2019**, 139, 53-66	7	68
58	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. *Journal of Thoracic Oncology*, **2018**, 13, 1692-1704	8.9	49
57	Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. *Nature Communications*, **2020**, 11, 2332	17.4	42
56	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*, **2018**, 155, 479-489.e7	13.3	36
55	Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. *Pharmacology & Therapeutics*, **2020**, 209, 107496	13.9	31
54	The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. *Scientific Reports*, **2018**, 8, 8703	4.9	31
53	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. *Annals of Surgery*, **2020**, 271, 527-533	7.8	27
52	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. *Critical Reviews in Oncology/Hematology*, **2018**, 123, 57-73	7	26
51	Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. *Journal of Cellular Physiology*, **2019**, 234, 1768-1779	7	25
50	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clinical Genitourinary Cancer*, **2018**, 16, e945-e951	3.3	22
49	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. *British Journal of Cancer*, **2017**, 117, 347-352	8.7	22
48	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. *Nature Medicine*, **2020**, 26, 992-994	50.5	19

47	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. *Future Oncology*, **2016**, 12, 1251-60	3.6	19
46	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. *Therapeutic Advances in Medical Oncology*, **2017**, 9, 183-188	5.4	17
45	The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes. *Journal of Cell Science*, **2014**, 127, 4381-95	5.3	15
44	Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2ACdc55. *Journal of Cell Biology*, **2013**, 202, 765-78	7.3	15
43	Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients. *Cancer Discovery*, **2021**,	24.4	15
42	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. *Oncologist*, **2019**, 24, 385-393	5.7	15
41	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. *Clinical Lung Cancer*, **2019**, 20, e413-e417	4.9	15
40	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. *Breast Cancer Research*, **2020**, 22, 33	8.3	14
39	Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. *Cells*, **2020** , 9,	7.9	13
38	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocrine-Related Cancer*, **2018**, 25, 607-618	5.7	13
37	The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. *Cancers*, **2021**, 13,	6.6	13
36	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. *Scientific Reports*, **2019**, 9, 12993	4.9	11
35	Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. *Breast Cancer Research and Treatment*, **2017**, 165, 365-373	4.4	10
34	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. *Cancers*, **2019**, 11,	6.6	10
33	Fasting-mimicking diet plus chemotherapy in breast cancer treatment. *Nature Communications*, **2020**, 11, 4274	17.4	10
32	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. *Cellular Oncology (Dordrecht)*, **2019**, 42, 815-828	7.2	9
31	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. *Oncotarget*, **2016**, 7, 44841-44847	3.3	9
30	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. *Clinical Breast Cancer*, **2019**, 19, e306-e318	3	9

29	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). *International Journal of Cancer*, **2019**, 144, 1704-1712	7.5	9
28	Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process. *Current Biology*, **2018**, 28, 28-37.e7	6.3	7
27	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. *Cancer Letters*, **2021**, 511, 77-87	9.9	7
26	Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. *Cell Metabolism*, **2021**, 33, 2247-2259.e6	24.6	6
25	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. *Cancers*, **2021**, 13,	6.6	6
24	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. *Frontiers in Oncology*, **2019**, 9, 902	5.3	5
23	Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. *Cells*, **2020**, 9,	7.9	5
22	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. *Future Oncology*, **2017**, 13, 1677-1683	3.6	4
21	Update on medical treatment of small intestinal neuroendocrine tumors. *Expert Review of Anticancer Therapy*, **2016**, 16, 969-76	3.5	4
20	DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. *Cells*, **2020**, 9,	7.9	4
19	Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. *Cancers*, **2020**, 12,	6.6	3
18	Urachal carcinoma: towards a precision medicine. *Translational Cancer Research*, **2016**, 5, S1307-S1310	0.3	3
17	Early Changes of the Standardized Uptake Values (SUV) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. *Cancers*, **2020**, 12,	6.6	3
16	Beyond Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. *Pharmaceuticals*, **2020**, 13,	5.2	3
15	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820927271	4.7	3
14	HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. *Cancers*, **2021**, 13,	6.6	3
13	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.. *Nature Cancer*, **2022**, 3, 251-261	15.4	3
12	Antitumor activity and efficacy of shorter longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920970081	5.4	2

List of Publications

11	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). *Clinical Cancer Research*, **2021**, 27, 3443-3455	12.9	2
10	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. *Case Reports in Oncology*, **2016**, 9, 432-439	1	2
9	Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters. *Oncology*, **2021**, 99, 84-95	3.6	2
8	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
7	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. *Cancers*, **2020**, 12,	6.6	1
6	The of a New Way to Value Myeloid Immunosuppression in Cancer. *Cancer Research*, **2019**, 79, 3169-3171	10.1	1
5	Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211006960	5.4	1
4	mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. *ESMO Open*, **2020**, 5, e000748	6	1
3	Cellular response upon proliferation in the presence of an active mitotic checkpoint. *Life Science Alliance*, **2019**, 2,	5.8	1
2	Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. *Developmental Cell*, **2021**, 56, 2607-2622.e6	10.2	1
1	Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.. *Therapeutic Advances in Medical Oncology*, **2022**, 14, 17588359221079123	5.4	1